The FDA approved VYKAT XR for Prader-Willi syndrome, while Scorpion Capital released a short report on Soleno Therapeutics comparing it to Zafgen's failure.
2 reports, 2 independent
Updated Aug 15
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA approved VYKAT XR for Prader-Willi syndrome, while Scorpion Capital released a short report on Soleno Therapeutics comparing it to Zafgen's failure.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Soleno Therapeutics (United States)
company in Redwood City, United States
Coverage
Newest first; wire copies grouped- Investing.comSoleno Therapeutics stock falls after Scorpion Capital short report Investing.com -- Soleno Therapeutics Inc (NASDAQ:SLNO) stock fell 13% Friday morning following a short report from Scorpion Capital
- BioPharma DiveSoleno sales of new Prader-Willi drug rise faster than expected This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive n